Cognizant and Boehringer Ingelheim collaborate on integrated cloud platform to improve therapy development
pharmafile | April 12, 2023 | News story | Medical Communications |
US-based Cognizant and biopharmaceutical company Boehringer Ingelheim have announced a partnership to collaborate on ensuring the quality, and increasing the speed of, medicinal therapy development.
Cognizant will leverage Veeva’s Development Cloud to bring Boehringer’s medicinal development processes and data into a connected ecosystem, named the One Medicine Platform. The aim is that this will increase interoperability and operational facilities.
The collaboration began with Cognizant’s analysis of Boehringer’s business and technology, which it then used to develop a programme roadmap and methodology for system integration. Veeva’s system will now be used to implement services such as programme development, system architecture, training, data migration, testing and validation services.
Srini Shankar, global head of Cognizant Life Sciences stated: “Utilising advanced technologies to improve the quality and delivery of novel medicines is a must for innovative pharmaceutical companies, and Boehringer Ingelheim stands out for their forward thinking in pursuing development of the One Medicine Platform. Veeva has been recognised as one of the fastest growing life sciences technology companies, and Cognizant is a skilled system integrator with the expertise necessary to simultaneously implement multiple Veeva platforms. We are proud to be working together to set new precedents in the way clinical, regulatory and quality functions come together to help accelerate the delivery of new life-saving therapies.”
“Achieving an end-to-end platform to help speed the development of life-changing therapies has been an elusive goal for many organisations, and we’re making that vision a reality. Our collaborations with Cognizant and Veeva are empowering us to advance this important programme that will positively impact patient lives,” commented Uli Brӧdl, senior vice president of Global Clinical Development at Boehringer Ingelheim.
James Spargo
